Furthermore, a longer-term (104-week) study in patients with T2D and stage 3 CKD found that dapagliflozin treatment was associated with an improvement in the urinary albumin:creatinine ratio (UACR) (-57.2% and -43.8% for those with dapagliflozin at 10 mg and 5 mg, respectively, at 104 weeks); however, these changes in UACR did not correlate with those changes in glycemic control (19). This evidence concerns the gene ALB and type 2 diabetes mellitus.